Glutamine in Burn Injury

Area of Science:

• Critical care medicine
• Nutritional science
• Burn management

Background:

• Burn injuries represent a severe metabolic stress with significant nutritional losses.
• These losses can impair immune function, delay wound healing, and increase the risk of organ injury and mortality.
• Glutamine (GLN) is a key amino acid with potential therapeutic benefits in critical illness.

Purpose of the Study:

• To evaluate the efficacy and safety of glutamine supplementation in burn-injured patients.
• To explore the potential of GLN in mitigating negative outcomes associated with severe burns.
• To inform ongoing clinical trials investigating GLN in burn care.

Main Methods:

• Review of experimental data and initial clinical trial findings on GLN in burn injury.
• Analysis of GLN's proposed mechanisms of action, including immune function and gut barrier maintenance.
• Consideration of current clinical recommendations and ongoing research.

Main Results:

• Experimental data suggest GLN has a strong mechanistic basis for improving outcomes in burn patients.
• Initial clinical trials indicate reduced mortality and hospital length of stay with GLN use.
• GLN supplementation has been associated with reduced gram-negative bacteremia, potentially through gut health preservation.

Conclusions:

• Glutamine (GLN) demonstrates a consistent signal of benefit in burn-injured patients, with no identified clinical risks.
• GLN supplementation is mechanistically supported and clinically suggested for use in burn injury.
• Further investigation in the RE-ENERGIZE trial is warranted to confirm these promising findings.